LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 1.74 USD Market Closed
Market Cap: 45.8m USD

LAVA Therapeutics NV
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

LAVA Therapeutics NV
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Revenue
$12m
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Revenue
$362.3m
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
30%
ProQR Therapeutics NV
NASDAQ:PRQR
Revenue
€16.1m
CAGR 3-Years
65%
CAGR 5-Years
11%
CAGR 10-Years
20%
Uniqure NV
NASDAQ:QURE
Revenue
$15.8m
CAGR 3-Years
-36%
CAGR 5-Years
21%
CAGR 10-Years
7%
argenx SE
XBRU:ARGX
Revenue
$2.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Revenue
$56.6m
CAGR 3-Years
7%
CAGR 5-Years
15%
CAGR 10-Years
36%
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
45.8m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.55 USD
Undervaluation 32%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Revenue?
Revenue
12m USD

Based on the financial report for Dec 31, 2024, LAVA Therapeutics NV's Revenue amounts to 12m USD.

What is LAVA Therapeutics NV's Revenue growth rate?
Revenue CAGR 3Y
34%

Over the last year, the Revenue growth was 77%. The average annual Revenue growth rates for LAVA Therapeutics NV have been 34% over the past three years .

Back to Top